Approved Products Not Yet Commercialized

Critical Accounting Policies and Estimates

Three months ended June 30, 2022 compared to June 30, 2021

Revenue, Cost of revenue and Gross profit:

Licensing fees increased by less than $0.1 million, or 3%. This increase is primarily due to licensing fees earned from the sale of Amphetamine ER Capsules and Amphetamine IR Tablets during the three months ended June 30, 2022 as compared to the comparable period of the prior fiscal year.

Our gross profit margin was 52% during the three months ended June 30, 2022 as compared to 50% during the comparable period of the prior fiscal year.

Non-cash compensation expense for the three months ended June 30, 2022 and June 30, 2021 was less than $0.1 million.

© Edgar Online, source Glimpses